A Phase 2 interventional study of COVID-19 mRNA vaccine and Placebo in COVID-19, sponsored by CanSino Biologics Inc.. Completed at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.
Sponsored by CanSino Biologics Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.
Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 2, and was the 6th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18–84 · Healthy volunteers
CNBG-Virogin Biotech (Shanghai) Ltd. · Sites in China
Ages 18–99 · Healthy volunteers
CNBG-Virogin Biotech (Shanghai) Ltd. · Sites in China
Ages 18–99 · Healthy volunteers
By country, each count listing its studies:
mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2021; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 157 across the 12 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
12 studies in COVID-19 by CanSino Biologics Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 12 studies in COVID-19 by CanSino Biologics Inc., this one is the 7th largest by enrollment, is one of 5 that started in 2022, is one of 2 in phase 2, and was the 9th registered.
CanSino Biologics Inc.’s COVID-19 studies by the year they started, since 2020.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, from their registry updates:
Among CanSino Biologics Inc.’s 12 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups. Each dose group (150 people) will be divided into 2 age groups (75 each):18 to 59 years old and ≥ 60 years old. The subjects will be randomized into vaccine group or placebo group in a ratio of 2:1. Subjects will complete 2 doses of vaccination on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group received 0.5 ml of the study vaccine or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria for exclusion of the first dose
Second dose exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
Biological: COVID-19 mRNA vaccine
2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
Biological: COVID-19 mRNA vaccine
2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
Biological: COVID-19 mRNA vaccine
2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
Biological: COVID-19 mRNA vaccine
2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
Biological: Placebo
2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
Biological: Placebo
2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
Biological: Placebo
2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
Biological: Placebo
2 doses of vaccine on Day 0 and Day 21
2 doses of placebo on Day 0 and Day 21
Immunogenicity of wild type neutralizing antibodies
GMT of wild type neutralizing antibodies
Time frame: 28 days after complete immunization
Immunogenicity of wild type neutralizing antibodies
Sero-conversation rate of wild type neutralizing antibodies
Time frame: 28 days after complete immunization
The incidence of adverse reactions (AR)
To evaluate the incidence of adverse reactions (AR) in all subjects
Time frame: Within 14 days of each vaccination
The incidence of adverse reactions (AR)
To evaluate the incidence of adverse reactions (AR) in all subjects
Time frame: Within 28 days of complete immunization
The incidence of adverse reactions (AR)
To evaluate the incidence of adverse reactions (AR) in all subjects
Time frame: Within 60 minutes of each vaccination
The incidence of SAE, MAE and AESI
To evaluation the incidence of SAE, MAE, and AESI in all subjects
Time frame: 12 months after complete vaccination
Immunogenicity of wild type neutralizing antibodies
Sero-conversation rate of wild type neutralizing antibodies
Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies
GMT of wild type neutralizing antibodies
Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies
GMI of wild type neutralizing antibodies
Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies
GMI of wild type neutralizing antibodies
Time frame: 28 days after complete immunization
Immunogenicity of anti-S-RBD Ig G antibodies
Sero-conversation rate of anti-S-RBD Ig G antibodies
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Immunogenicity of anti-S-RBD Ig G antibodies
GMC of anti-S-RBD Ig G antibodies
Time frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Immunogenicity of anti-S-RBD Ig G antibodies
GMI of anti-S-RBD Ig G antibodies
Time frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity
The response levels and positive rates of IL-2 produced by S protein RBD by ICS in the first 15 subjects in each group
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity
The response levels and positive rates of IL-4 produced by S protein RBD by ICS in the first 15 subjects in each group
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity
The response levels and positive rates of IL-5 produced by S protein RBD by ICS in the first 15 subjects in each group
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity
The response levels and positive rates of IL-17 produced by S protein RBD by ICS in the first 15 subjects in each group
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity
The response levels and positive rates of IFN-γ produced by S protein RBD by ICS in the first 15 subjects in each group
Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Changes in laboratory indicators
Changes in white blood cell count
Time frame: Before 1st dose and 28 days after second dose
Changes in laboratory indicators
Changes in neutrophils
Time frame: Before 1st dose and 28 days after second dose
Changes in laboratory indicators
Changes in lymphocyte count
Time frame: Before 1st dose and 28 days after second dose
Changes in laboratory indicators
Changes in platelet count
Time frame: Before 1st dose and 28 days after second dose
VOC/VOI serum cross neutralization
To evaluated the level of VOC/VOI serum cross neutralization results in all subjects.
Time frame: 28 days after complete immunization
Ran from Jul 2022 to primary completion in Sep 2022, 2 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 2 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA COVID-19 Vaccine